Fast-track Diagnosis for Lung Cancer Suspects With PET-CT and EUS
A Prospective, Open, Single Center, Study of One-day Diagnostic Track for Lung Cancer Suspects From Chest X-ray Using PET-CT and Subsequent Multiple Endoscopic Investigations. (Including Bronchoscopy, EUS-FNA)
1 other identifier
observational
297
1 country
1
Brief Summary
Patients who are admitted to the outpatient pulmonology department by a general practitioner or specialist with a chest X-ray suspicious for lung cancer with an age between 18 and 80 years are suitable for participation. The X-ray and referral are studied by a chest physician (by phone or fax ). Selected patients are invited to enter the study after answering a questionnaire by phone (p. 31). The questionnaire screens patients' interest, co-morbidity and medication use. Informed consent forms, patient information forms and a time table for the diagnostic day are provided by mail or E-mail in cases where time gets short. Waiting time to enter the study will be no longer than one week. Hundred patients will be recruited by means of informed consent. Patients will be admitted at the pulmonary ward for the study day and will be accompanied by nurses. All patients will get PET-CT scanning in the morning of the study day. Depending on the location of lesions seen on PET-CT, further invasive diagnostic procedures will be planned for the afternoon. Mediastinal and adjacent structures will be analysed with EUS-FNA. Mediastinal staging will be done with bronchoscopy alone for central located tumors, peripherally located lesions will be analysed with EUS-FNA or bronchoscopy. The percentage of patients in which this diagnostic track leads to a diagnosis and tumor stage in one day will be determined. The number of tests and diagnostic procedures needed to obtain a diagnosis, including tumor stage (especially final stage NSCLC) and function tests, will be compared with a historical matched study group. This historical study group is chosen from an era before the availability of integrated PET-CT and ultrasound guided endoscopic tools and meets the same inclusion and exclusion criteria as the patients in this study. The timelines from initial chest X-ray to diagnostic day to informing the patient to start of treatment will be determined. These figures will be compared with the historical study group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2006
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2006
CompletedFirst Submitted
Initial submission to the registry
November 9, 2007
CompletedFirst Posted
Study publicly available on registry
November 12, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedApril 8, 2013
April 1, 2013
3.3 years
November 9, 2007
April 5, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of patients that will have a definitive diagnosis and final stage NSCLC in one day
1 day
Secondary Outcomes (1)
Number of tests and procedures that have been performed. Patient satisfaction with the one-day procedure. Sensitivity of EUS-FNA and EBUS-TBNA when immunohistochemical analysis is added to investigate false negative procedures.
2 years
Study Arms (1)
A
Fast-track diagnosis
Interventions
Eligibility Criteria
Patients suspected of lung cancer
You may qualify if:
- patients with a suspicion of lung cancer on chest X-ray
- age between 18-85 years
- informed consent.
You may not qualify if:
- comorbidity (alcoholabuse, drugsabuse and limiting psychiatric disease)
- non-compliance
- previous diagnostic tests for the suspicious X-ray (endoscopy, CT)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Isalalead
Study Sites (1)
Isala Klinieken
Zwolle, 8011 JW, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
J. Stigt, Drs.
Isala
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
November 9, 2007
First Posted
November 12, 2007
Study Start
September 1, 2006
Primary Completion
January 1, 2010
Study Completion
January 1, 2010
Last Updated
April 8, 2013
Record last verified: 2013-04